REFERENCES
1. Akinyemiju T, Abera S, Ahmed M, et al; Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683-91.
2. Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: current best practice and future direction. Gastroenterology 2019;157:54-64.
3. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med 2014;11:e1001624.
4. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123:357-60.
5. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
6. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-80.
7. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317-70.
8. Association for the Study of the Liver. Electronic address: [email protected], European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
9. Covey AM. Hepatocellular carcinoma: updates to screening and diagnosis. J Natl Compr Canc Netw 2018;16:663-5.
10. Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med 2012;27:861-7.
11. Sloane D, Chen H, Howell C. Racial disparity in primary hepatocellular carcinoma : tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc 2006;98:1934-9.
12. Ha J, Yan M, Aguilar M, et al. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer 2016;122:2512-23.
13. Singal AG, Yopp AC, Gupta S, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer Prev Res 2012;5:1124-30.
14. El-Serag HB, Alsarraj A, Richardson P, et al. Hepatocellular carcinoma screening practices in the department of veterans affairs: findings from a national facility survey. Dig Dis Sci 2013;58:3117-26.
15. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst 2002;94:334-57.
16. Parikh ND, Tayob N, Al-Jarrah T, et al. Barriers to surveillance for hepatocellular carcinoma in a multicenter cohort. JAMA Netw Open 2022;5:e2223504.
17. Beal EW, Owen M, McNamara M, McAlearney AS, Tsung A. Patient-, provider-, and system-level barriers to surveillance for hepatocellular carcinoma in high-risk patients in the USA: a scoping review. J Gastrointest Cancer 2023;54:332-56.
18. Simmons OL, Feng Y, Parikh ND, Singal AG. Primary care provider practice patterns and barriers to hepatocellular carcinoma surveillance. Clin Gastroenterol Hepatol 2019;17:766-73.
19. Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2015;13:791-8.e1.
20. Glaser BG. More grounded theory methodology: a reader. Available from: https://www.amazon.com/More-Grounded-Theory-Methodology-reader/dp/188415607X[Last accessed on 25 Oct 2023].
21. Crabtree B, Miller W. Doing qualitative research. Available from: https://www.amazon.com/CRABTREE-QUALITATIVE-RESEARCH-Research-Paperback/dp/0761914986 [Last accessed on 25 Oct 2023].
22. Constas MA. Qualitative analysis as a public event: the documentation of category development procedures. Am Educ Res J 1992;29:253-66.
23. ATLAS.ti (Software). Available from: https://atlasti.com/ [Last accessed on 25 Oct 2023].
24. Beste LA, Ioannou GN, Yang Y, Chang MF, Ross D, Dominitz JA. Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder. Clin Gastroenterol Hepatol 2015;13:172-9.
25. Russo MW, Fix OK, Koteish AA, et al. Modeling the hepatology workforce in the United States: a predicted critical shortage. Hepatology 2020;72:1444-54.
26. Russo MW, Koteish AA, Fuchs M, Reddy KG, Fix OK. Workforce in hepatology: update and a critical need for more information. Hepatology 2017;65:336-40.
27. Ladhani S, Ohri A, Wong RJ. Disparities in hepatocellular carcinoma surveillance: dissecting the roles of patient, provider, and health system factors. J Clin Gastroenterol 2020;54:218-26.
28. Toyoda H, Huang DQ, Le MH, Nguyen MH. Liver care and surveillance: the global impact of the COVID-19 pandemic. Hepatol Commun 2020;4:1751-7.
29. Mancebo G, Solé-Sedeño JM, Membrive I, et al. Gynecologic cancer surveillance in the era of SARS-CoV-2 (COVID-19). Int J Gynecol Cancer 2021;31:914-9.
30. D'Ovidio V, Lucidi C, Bruno G, Lisi D, Miglioresi L, Bazuro ME. Impact of COVID-19 pandemic on colorectal cancer screening program. Clin Colorectal Cancer 2021;20:e5-11.
31. Vose JM. Delay in cancer screening and diagnosis during the COVID-19 pandemic: what is the cost? Oncology 2020;34:343.
32. London JW, Fazio-Eynullayeva E, Palchuk MB, Sankey P, McNair C. Effects of the COVID-19 pandemic on cancer-related patient encounters. JCO Clin Cancer Inform 2020;4:657-65.
33. Zeng G, Gill US, Kennedy PTF. Prioritisation and the initiation of HCC surveillance in CHB patients: lessons to learn from the COVID-19 crisis. Gut 2020;69:1907-12.
34. Paredes AZ, Hyer JM, Beal EW, et al. Impact of skilled nursing facility quality on postoperative outcomes after pancreatic surgery. Surgery 2019;166:1-7.
35. Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and monitoring of hepatocellular carcinoma during the COVID-19 pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30.
36. Seo YS, Jang BK, Um SH, et al. Validation of risk prediction models for the development of HBV-related HCC: a retrospective multi-center 10-year follow-up cohort study. Oncotarget 2017;8:113213-24.
37. Goldberg DS, Taddei TH, Serper M, et al. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology 2017;65:864-74.
38. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. Hepatology 2017;65:875-84.
39. Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. Am J Med 2015;128:90.e1-7.
40. Guo A, Pomenti S, Wattacheril J. Health disparities in screening, diagnosis, and treatment of hepatocellular carcinoma. Clin Liver Dis 2021;17:353-8.
41. Fitzmorris P, Singal AK. Surveillance and diagnosis of hepatocellular carcinoma. Gastro Hepat 2015;11:38-46.
42. Aberra FB, Essenmacher M, Fisher N, Volk ML. Quality improvement measures lead to higher surveillance rates for hepatocellular carcinoma in patients with cirrhosis. Dig Dis Sci 2013;58:1157-60.
43. Singal AG, Tiro JA, Marrero JA, et al. Mailed outreach program increases ultrasound screening of patients with cirrhosis for hepatocellular carcinoma. Gastroenterology 2017;152:608-15.e4.
44. Singal AG, Tiro JA, Murphy CC, et al. Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis: a randomized clinical trial. Hepatology 2019;69:121-30.
45. Yoder L, Mladenovic A, Pike F, et al. Attendance at a transitional liver clinic may be associated with reduced readmissions for patients with liver disease. Am J Med 2022;135:235-43.e2.
46. Kennedy NA, Rodgers A, Altus R, McCormick R, Wundke R, Wigg AJ. Optimisation of hepatocellular carcinoma surveillance in patients with viral hepatitis: a quality improvement study. Intern Med J 2013;43:772-7.
47. Shaw J, Patidar KR, Reuter B, et al. Focused education increases hepatocellular cancer screening in patients with cirrhosis regardless of functional health literacy. Dig Dis Sci 2021;66:2603-9.
48. Artinyan A, Mailey B, Sanchez-Luege N, et al. Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States. Cancer 2010;116:1367-77.
49. Nam JY, Lee JH, Kim HY, et al. Oral medications enhance adherence to surveillance for hepatocellular carcinoma and survival in chronic hepatitis B patients. PLoS One 2017;12:e0166188.
50. Cabrie T, Wheeler E, Jacqui R, et al. The challenge of liver cancer surveillance in general practice: Do recall and reminder systems hold the answer? Available from: https://www.racgp.org.au/afp/2017/november/the-challenge-of-liver-cancer-surveillance/ [Last accessed on 27 Oct 2023].
51. Cahill JA, Rizvi S, Saeian K. Assessment of adherence to baseline quality measures for cirrhosis and the impact of performance feedback in a regional VA medical center. Am J Med Qual 2018;33:262-8.
52. Rogal SS, Yakovchenko V, Gonzalez R, et al. The hepatic innovation team collaborative: a successful population-based approach to hepatocellular carcinoma surveillance. Cancers 2021;13:2251.
